These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 18178958)
1. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958 [TBL] [Abstract][Full Text] [Related]
2. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Agarwala SS; Kirkwood JM Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513 [TBL] [Abstract][Full Text] [Related]
3. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739 [TBL] [Abstract][Full Text] [Related]
5. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213 [TBL] [Abstract][Full Text] [Related]
6. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R; J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697 [TBL] [Abstract][Full Text] [Related]
7. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263 [TBL] [Abstract][Full Text] [Related]
8. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675 [TBL] [Abstract][Full Text] [Related]
10. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide and cisplatin in avdanced malignant melanoma. Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103 [TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500 [No Abstract] [Full Text] [Related]
15. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216 [TBL] [Abstract][Full Text] [Related]
16. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632 [TBL] [Abstract][Full Text] [Related]
17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250 [TBL] [Abstract][Full Text] [Related]
18. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674 [TBL] [Abstract][Full Text] [Related]
19. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494 [TBL] [Abstract][Full Text] [Related]
20. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]